IPF mHealth Exercise Study

Inclusion Criteria: * Age 40-80 yrs at randomization * Diagnosis of idiopathic pulmonary fibrosis (IPF), consistent with the ATS 2018 Guidelines * Percent Forced Vital Capacity (%FVC) ≥50% * Percent Carbon Monoxide Diffusing Capacity (%DLCO) ≥30% * Willing and able to participate in an exercise regimen * Ambulatory without the use of an assistive device * Stable on antifibrotic therapy (pirfenidone or nintedanib) at least 3 months * No changes in other medication for at least 4 wks before enrollment * Must be able to read, write, and verbally communicate in English Exclusion Criteria: * Forced expiratory volume in one second (FEV1)/FVC ratio \<0.7 after administration of bronchodilator at screening * Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization * Known explanation for interstitial lung disease * History of asthma or chronic obstructive pulmonary disease * Active infection * Ongoing IPF treatments including investigational therapy, immunosuppresents (other than prednisone 20 mg daily and below) and cytokine modulating agents * Participation in a supervised exercise program including pulmonary rehab within the previous 12 months * History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months * Major orthopedic, psychiatric, neurological, or other conditions that would impair performance of the study exercise outcomes * Require \>5LPM supplemental O2 at rest * Currently pregnant